PMGC Holdings ELAB
NASDAQ ELAB
$6.66 +0.56 (+9.18%)
At close: Aug 21, 2026 · 4:00 PM EDT

PMGC Holdings (ELAB) Cash & Equivalents (2022 - 2026)

PMGC Holdings (ELAB) posted Cash & Equivalents of $14.4 million for Q1 2026, up 165.71% sequentially from $5.4 million in Q4 2025, and up 167.58% YoY from $5.4 million in Q1 2025.

PMGC Holdings (ELAB) Cash & Equivalents (2022 - 2026) Analysis & Trends

PMGC Holdings has reported Cash & Equivalents for 5 years, with the latest figure at $14.4 million in Q1 2026.

  • Quarterly Cash & Equivalents rose 167.58% year-over-year to $14.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.4 million (up 167.58% YoY) and the FY2025 annual result came in at $5.4 million, up 35.59% from the prior year.
  • Cash & Equivalents improved to $14.4 million in Q1 2026 per ELAB's latest filing, from $5.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $1.6 billion in Q3 2022 and troughed at $100034.0 in Q2 2024.
  • A 5-year average of $108.6 million and a median of $4.0 million in 2024 frame the typical range for Cash & Equivalents.
  • The sharpest annual moves came in 2023 and 2025: Cash & Equivalents slumped 99.97% in 2023, then surged 5580.7% in 2025.
  • Over 5 years, Cash & Equivalents stood at $1.2 million in 2022, then jumped by 188.06% to $3.3 million in 2023, then climbed by 19.77% to $4.0 million in 2024, then surged by 35.59% to $5.4 million in 2025, then surged by 165.71% to $14.4 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods registered $14.4 million, $5.4 million, and $7.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash & Equiv. (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 6.14 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 2.46 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 3.58 Bn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 1.72 Bn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 5.10 Bn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 1.71 Bn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn 8.93 Bn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn 544.80 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 811.99 Mn
10 PMGC Holdings 31.22 Mn 12.43 Mn 385,691.00 18.14 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 14.35 Mn
Dec 31, 2025 5.40 Mn
Sep 30, 2025 7.70 Mn
Jun 30, 2025 5.68 Mn
Mar 31, 2025 5.36 Mn
Dec 31, 2024 3.98 Mn
Sep 30, 2024 6.43 Mn
Jun 30, 2024 100,034.00
Mar 31, 2024 943,797.00
Dec 31, 2023 3.33 Mn
Sep 30, 2023 476,855.00
Jun 30, 2023 601,265.00
Mar 31, 2023 1.05 Mn
Dec 31, 2022 1.15 Mn
Sep 30, 2022 1.57 Bn